medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 6

<< Back Next >>

Ann Hepatol 2012; 11 (6)

Splenectomy in cirrhosis with hypersplenism: improvement in cytopenias, child’s status and institution of specific treatment for hepatitis C with success

Kedia S, Goyal R, Mangla V, Kumar A, Shalimar S, Das P, Pal S, Sahnib P, Acharya SK

Language: English
References: 35
Page: 921-929
PDF size: 121.91 Kb.


ABSTRACT

Introduction. Hypersplenism in cirrhosis is not infrequent and may compromise with quality of life and therapy. Splenectomy is a therapeutic option, but information on results of splenectomy is scarce. Material and methods. Consecutive patients with cirrhosis who underwent splenectomy between 2001-2010 were included in the study. Safety, efficacy of splenectomy and subsequent influence on therapy were evaluated. Results. Thirty three patients (mean age 30.9 ± 11.6 years, 19 men, viral 48.5%, autoimmune 15.1%, cryptogenic 36.4%) underwent splenectomy. Twenty were Child’s A, 13 Child’s B. Twenty patients had › 6 months follow up. Common indications were inability to treat with interferon, transfusion-dependent anemia, recurrent mucosal bleeds, and large spleen compromising quality of life. Median hospital stay was 7 (4-24) days. There was no splenectomy related mortality. Twenty three (70%) patients had post-operative complications, most commonly infections. Two patients required percutaneous drainage of post-operative collections, and 1 needed re-exploration for intra-abdominal bleed. Subsequent to splenectomy platelet count (44,000 to 151,000/mm3, p ‹ 0.01) and TLC (2,500 to 13,400/mm3, p ‹ 0.01) had sustained increase in all patients except one. Five HCV cirrhotics completed interferon and ribavirin therapy, 4 achieved sustained viral response. The quality of life improved and there was no recurrence of infections, mucosal bleed or anemia requiring transfusions in any patient. In patients on long term follow up (median duration 27 months), the median Child’s score improved from 6 at baseline to 5 at follow up (p ‹ 0.05). Conclusions. Splenectomy was safe and effective in patients with cirrhosis, and improved therapeutic options as well as Child’s score.


REFERENCES

  1. Liangpunsakul S, Sithat M, Ulmer B, Chalasani. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sciences 2003; 326: 111-16.

  2. Bashour N, Teran JC, Mullenet KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000; 95: 2936-9.

  3. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazella G, Ascione A, et al., Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.

  4. Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a longterm observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.

  5. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafrii W, Tateishi R, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. DOI: 10.1007/s12072-012-9342-y Online First

  6. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C (review). Gastroenterology 2002; 123: 1711-19.

  7. Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, Luketic VA, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46: 371-79.

  8. Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, Kania RJ, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995; 42: 907-12.

  9. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-36.

  10. Sakai T, Shiraki K, Inoue H, Sugimoto K, Ohmori S, Murata K, Takase K, et al. Complications of Partial Splenic Embolization in Cirrhotic Patients. Digestive Diseases and Sciences 2002; 47: 388-91.

  11. Noguchi H, Hirai K, Aoki Y, Sakata K, Tanikawa K. Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology 1995; 22: 1682-8.

  12. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-8.

  13. Anna S, Lok F, Brian J. McMahon. AASLD Practice Guidelines: Chronic Hepatitis B: Update 2009. Hepatology 2009; 50 (3).

  14. Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD Practice Guidelines: Diagnosis, Management, and treatment of Hepatitis C: An Update. Hepatology 2009; 49(4).

  15. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010; 4: 548-61.

  16. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatology 1999; 31: 929-38.

  17. Pande GK, Reddy VM, Kar P, Sahni P, Berry M, Tandon BN, Nundy S. Operations for portal hypertension due to extrahepatic obstruction: results and 10 year follow up. Br Med J (Clin Res Ed) 1987; 31(295): 1115-17.

  18. Pal S, Radhakrishna P, Sahni P, Pande GK, Nundy S, Chattopadhyay TK. Prophylactic surgery in non-cirrhotic portal fibrosis: is it worthwhile? Indian J Gastroenterol 2005; 24: 239-42.

  19. Dindo D, Demartines N, Clavien PA. Classification of surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey. Ann Surg 2004; 240: 205-13.

  20. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al. Clinical Management of Hepatocellular carcinoma: conclusions of the Barcelona– 2000 EASL Conference. J Hepatol 2001; 35: 421-30.

  21. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.

  22. Hama T, Takifuji K, Uchiyama K, Tani M, Kawai M, Yamaue H. Laparoscopic splenectomy is a safe and effective procedure for patients with splenomegaly due to portal hypertension. J Hepatobiliary Pancreat Surg 2008; 15: 304-9.

  23. Zhu JH, Wang YD, Ye ZY, Zhao T, Zhu YW, Xie ZJ, Liu JM. Laparoscopic versus open splenectomy for hypersplenism secondary to liver cirrhosis. Surg Laparosc Endosc Percutan Tech 2009; 19: 258-62.

  24. Wang Y, Zhan X, Zhu Y, Xie Z, Zhu J, Ye Z. Laparoscopic splenectomy in portal hypertension: a single surgeon 13- year experience. Surg Endosc 2010; 24: 1164-9.

  25. Cai YQ, Zhou J, Chen XD, Wang YC, Wu Z, Peng B. Laparoscopic splenectomy is an effective and safe intervention for hypersplenism secondary to liver cirrhosis. Surg Endosc 2011 [Epub ahead of print].

  26. Tomikawa M, Akahoshi T, Sugimachi K. Laparoscopic splenectomy may be a superior supportive intervention for cirrhotic patients with hypersplenism. J Gastroenterol Hepatol 2010; 25: 397-402.

  27. Mahmoud A, Amin E, Mohamed M, El Gendy EIbrahim E. Dawoud. Partial Splenic Embolization Versus Splenectomy for the Management of Hypersplenism in Cirrhotic Patients. World J Surg 2009; 33: 1702-10.

  28. Acharya SK, Madan K, Dattagupta S, Panda SK. Viral Hepatitis in India. Natl Med J India 2006; 19: 203-17.

  29. Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.

  30. Kercher KW, Carbonell AM, Heniford BT, Matthews BD, Cunningham DM, Reindollar RW. Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension. J Gastrointest Surg 2004; 8: 120-6.

  31. Hayashi PH, Mehia C, Joachim Reimers H, Solomon HS, Bacon BR. Splenectomy for Thrombocytopenia in Patients with Hepatitis C Cirrhosis. J Clin Gastroenterol 2006; 40: 740-4.

  32. Akahoshi T, Tomikawa M, Korenaga D, Ikejiri K, Saku M, Takenaka K. Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Surg Endosc 2010; 24: 680-5.

  33. Shigekawa Y, Uchiyama K, Takifuji K, Ueno M. A laparoscopic splenectomy allows the induction of antiviral therapy for patients with cirrhosis associated with hepatitis C virus. Am Surg 2011; 77: 174-9.

  34. Ikezawa K, Naito M, Yumiba T, Iwahashi K, Onishi Y, Kita H, Nishio A, et al. Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection. J Viral Hepat 2010; 17: 488-92.

  35. CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1997; 46: 1-24.




2020     |     www.medigraphic.com